Hyperuricemia and gout are common purine metabolic diseases, associated with chronic kidney disease, cardiovascular disease and other adverse outcomes. Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a foundational treatment for hypoglycemic, weight loss, renal and cardiovascular protection, also may reduce uric acid levels and therefore reduce the incidence of gout. This article will elaborate on several aspects: the indication of SGLT2i, the clinical studies on SGLT2i lowering serum uric acid level and its mechanism, SGLT2i reducing the risk of gout attack, the association of the benefit of SGLT2i in heart failure with hyperuricemia and gout. This article′s objective is to review the research progress of SGLT2i on hyperuricemia and gout, for purpose of helping clinical doctors to better understand the beneficial effect of SGLT2i lowering uric acid level and gout attack